• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaccinex Inc (NQ: VCNX )

    6.720 -0.180 (-2.61%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,602
    Open 7.050
    Bid (Size) 6.500 (1)
    Ask (Size) 6.990 (2)
    Prev. Close 6.900
    Today's Range 6.630 - 7.100
    52wk Range 4.432 - 64.89
    Shares Outstanding 65,941,086
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
    Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression 
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
    From Vaccinex, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -36.32%
    -36.32%
    1 Month
    +8.76%
    +8.76%
    3 Month
    +14.87%
    +14.87%
    6 Month
    -26.44%
    -26.44%
    1 Year
    -88.57%
    -88.57%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    VCNX Stock Earnings: Vaccinex Reported Results for Q1 2024
    Via InvestorPlace
    VCNX Stock Earnings: Vaccinex Reported Results for Q4 2023
    Via InvestorPlace
    Why Vaccinex (VCNX) Stock Is Trading Lower
    Via Benzinga
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Vaccinex, Inc.
    Via GlobeNewswire
    Why Vaccinex (VCNX) Stock Is Popping Off
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Vaccinex Reports 2023 Financial Results and Provides Corporate Update
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex, Inc. Announces Reverse Stock Split
    From Vaccinex, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Vaccinex Announces Pricing of $3.7 Million PIPE Financing
    From Vaccinex, Inc.
    Via GlobeNewswire
    Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
    From Vaccinex, Inc.
    Via GlobeNewswire
    Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
    From Vaccinex, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.